RxDoctor Payments Data

Kelly Malcom, APRN

Psychiatric/Mental Health · Hot Springs, ARNPI 1043705726

Payments from drug & device makers

$1,945in general payments, 2019–2025

Across 107 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$556
  • Neurocrine Biosciences, Inc.$278
  • Otsuka America Pharmaceutical, Inc.$237
  • Johnson & Johnson$235
  • Axsome Therapeutics, Inc.$197
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$161
  • plus $281 from 6 others

What the payments were for

  • Food & beverage$1,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,945 in reported general payments places this provider in the 70th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$5,563
Medicare patients
11
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine35$176,356
IngrezzaValbenazine Tosylate11$104,015
VraylarCariprazine Hcl19$37,779
AuvelityDextromethorphan Hbr/Bupropion17$19,259
Aripiprazole59$2,786
Duloxetine Hcl51$1,990
Perphenazine15$1,878
Paliperidone ErPaliperidone12$1,284
Fluoxetine Hcl76$1,198
Olanzapine40$910
Buspirone Hcl46$746
Diazepam51$602
Lamotrigine86$539
Trazodone Hcl34$480
Carbamazepine12$466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$82$176,35635 claims
Neurocrine Biosciences, Inc.Ingrezza$278$104,01511 claims
AbbVieVraylar$556$37,77919 claims
Axsome Therapeutics, Inc.Auvelity$197$19,25917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →